In this episode, the Kaleidoscope team talked all things marijuana including the use of cannabidiol to treat marijuana dependence, the history and lore of the drug, and a major flaw in the marijuana supply informing US-based research.
- Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D., Thomas, E. M., Astbury, D., … & Bloomfield, M. A. (2020). Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry, 7(10), 865-874.
- Schwabe, A. L., Hansen, C. J., Hyslop, R. M., & McGlaughlin, M. E. (2019). Research grade marijuana supplied by the National Institute on Drug Abuse is genetically divergent from commercially available Cannabis. bioRxiv, 592725.
Dr Dawn N. Albertson
Summarising Dawn’s academic trajectory is not easy but, roughly: behaviour, drugs, brains on drugs and then educating people about brains, behaviour, and drugs.View profile
Prof Sukhi S. Shergill
A multilingual MD/PhD, Sukhi is a Professor of Psychiatry and Systems Neuroscience at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London and a PsychiatristView profile
Dr Derek K. Tracy
Derek is the Medical Director of West London NHS Trust, and a senior lecturer at King's College London and University College London.View profile
Dr Dan W. Joyce
Certified genius and MD/PhD wunderkid, Dan works at the Department of Psychiatry, University of Oxford and is a Consultant Psychiatrist with Oxford Health NHS Foundation Trust. Veggie, data head, and a research purist, Dan’s signature acerbic wit brings comedy and clarity to all things complicated.View profile